Clarity Pharmaceuticals Ltd (ASX:CU6) has reported positive results from a further stage of its theranostic prostate cancer trial – known as SECuRE – with data from all 3 patients in a fourth cohort indicating the safety of drug Cu-SAR-bisPSMA at its highest dose. SECuRE is a Phase I/IIa theranostic trial which aims to identify and treat patients who have prostate-specific membrane antigen (PSMA)-expressing metastatic castrate-resistant prostate cancer (mCRPC). The overall aim of the trial – which involves around 44 participants in the United States and Australia – is assessment of how safe an…